PRINCETON, N.J.—2020年9月1日. Certara, the global leader in biosimulation, today announced changes to its board of directors, which took effect 2020年8月26日.
After successfully transitioning the leadership of Certara to Chief Executive Officer William Feehery, Edmundo Muniz has decided to step down from the board. William Klitgaard, who has served on the board for 3 years, has decided to step down from the board.
Matthew Walsh has joined the board of Certara. He is the chief financial officer at Organon & Co., a global pharmaceutical business within Merck that is planned to be spun off in 2021. Before joining Organon, Mr. Walsh was at Allergan where he served as executive vice president and chief financial officer. Previously, he was at Catalent for 10 years as chief financial officer.
Ethan Waxman, director at EQT Partners, has joined the board after serving as a board observer for 3 years. He joined EQT Partners in 2015, where he has been involved in the investments in Press Ganey, Waystar and the initial investment in Certara. Previously, Mr. Waxman worked at Warburg Pincus.
“It is a pleasure to welcome Matt and Ethan to the board. We look forward to their valuable perspectives and contributions,” said Sheri McCoy, chair of Certara’s board of directors. “We also extend our deep gratitude and well wishes to Edmundo and William for their years of service.”
